ArticleJournal of general internal medicine2025
Initiating Medications for Opioid Use Disorder in Hospitalized Incarcerated Patients.
Article in Journal of general internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Opioid use disorder (OUD) affects millions in the USA, with a growing disparity among Black men, a patient population which also suffers higher rates of incarceration. Medications for opioid use disorder (MOUD), specifically buprenorphine and methadone, significantly reduce mortality, though remain underutilized particularly within the incarcerated population. Post-release opioid overdose is the leading cause of mortality among recently incarcerated individuals, so opportunities to offer life-saving treatment must be capitalized upon. Hospitalization offers an ideal time to start MOUD, yet those incarcerated face unique barriers to initiating and continuing such medication. Initiating MOUD can improve post-release opioid-related outcomes but requires a well-coordinated approach to treatment. Here, we review the importance of MOUD for the incarcerated population and how hospital-based clinicians can address patient-, provider-, and system-level obstacles to deliver equitable, evidence-based treatment for this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.